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Despite evidence of drug efficacy in
mouse models of cancer, many novel anti-
cancer agents fail in human cancer patients
because of unacceptable toxicity or poor
efficacy [1]. Naturally occurring tumors in
dogs and other animals have clinical and
biological similarities to human cancers
that are difficult to replicate in other model
systems. A recently launched cooperative
effort, the National Cancer Institute’s
(NCI’s) Comparative Oncology Trials
Consortium (COTC; http://ccr.cancer.
gov/resources/cop/COTC.asp), now pro-
vides infrastructure and resources needed
to integrate these naturally occurring
cancer models into the development of
new human cancer drugs, devices, and
imaging techniques.
Disappointments in Cancer
Drug Development
Murine cancer models have been ex-
tremely useful for analyzing the biology of
pathways involved in cancer initiation,
promotion, and progression. However,
they frequently do not adequately repre-
sent many of the features that define
cancer in humans, including long periods
of latency, genomic instability, and the
heterogeneity of both tumor cells and their
surrounding microenvironment. Most im-
portantly, the complex biology of cancer
recurrence and metastasis, integral to
outcomes in human patients, are not
appreciably reproduced in the convention-
al mouse models used in cancer drug
development. Furthermore, in many cases,
there has been inadequate consideration
of relevant exposures for new drugs that
are evaluated in mice. The development
and approval of novel cancer drugs is
lengthy and expensive [2–5]; therefore,
additional models that better represent the
human disease are needed.
Current drug development pathways
are frequently unidirectional. Novel agents
are assessed in conventional preclinical
models of efficacy and toxicity before
moving into human clinical trials where
they either fail or succeed. Particularly
with novel targeted therapies the conven-
tional paradigms of toxicity studies con-
ducted in healthy animals followed by
Phase I and Phase II human trials leave
unanswered many important questions on
the ‘‘best use’’ of these drugs [6]. Trans-
lational drug development studies in pet
dogs with cancer provide an opportunity
to answer these questions by serving as an
intermediary between conventional pre-
clinical models and human clinical trials
[7–9]. In these dogs, cancers develop
naturally in the context of an intact
immune system and with a syngeneic host
and tumor microenvironment. Similar
environmental, nutrition, age, sex, and
reproductive factors lead to tumor devel-
opment and progression in human and
canine cancers. They share similar fea-
tures such as histologic appearance, tumor
genetics, biological behavior, molecular
targets, therapeutic response, and unfor-
tunately, acquired resistance, recurrence,
and metastasis.
Clinical trials in pet dogs are not
constrained by traditional Phase I, Phase
II, and Phase III trial designs. This allows
novel agents to be offered to pet dogs
before conventional therapies or during
the period of minimal residual disease. Pet
owners are highly motivated to seek novel
options for management of cancer in their
pets, especially if conventional treatments
do not meet their goals. A pet owner’s
decision to pursue an investigational
treatment is often influenced by the risks
associated with this therapy compared to
conventional therapy, as well as their
expectations for outcomes and reduced
costs for care provided by an investiga-
tional trial. Additionally, many pet owners
are motivated by the opportunity to
contribute to the advancement of cancer
treatment for future human and canine
patients.
The study of cancer biology and
therapy in animals with naturally occur-
ring cancers, referred to as comparative
oncology, is not a novel concept. Indeed,
over the last 30–40 years investigators
have used this approach to make impor-
tant contributions to the understanding
and practice of human oncology in fields
such as basic tumor biology and immu-
nology [10–14], radiation biology [15],
hyperthermia [16], and systemic therapies
for a variety of cancers including osteo-
sarcoma, lymphoma, melanoma, and oth-
ers [12,17–22]. One historical limitation to
the widespread use and integration of the
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infrastructure to coordinate animal health
professionals with the human oncology
community, drug developers, and basic
scientists.
Comparative Oncology Trials
Consortium Program
Infrastructure
The COTC was launched through the
intramural NCI’s Center for Cancer
Research–Comparative Oncology Pro-
gram. The COTC operates as a collabo-
rative effort between the NCI and extra-
mural academic comparative oncology
centers and functions to design and
execute clinical trials in dogs with cancer
in collaboration with the pharmaceutical
industry and nongovernmental groups
interested in cancer drug development.
Support for the oversight and manage-
ment of the COTC comes from the NCI.
Trial sponsors, most often pharmaceutical
companies, support the clinical costs of
studies conducted by the COTC academic
centers. The goal of this effort is to answer
biological questions that can inform the
development path of novel agents for
future use in human cancer patients in a
timely and integrated manner. Trials
conducted by the COTC are designed to
include clinical and biological endpoints,
i.e., pharmacokinetics and pharmacody-
namics, so as to optimally inform the
design of early phase human trials. Trials
are carried out at COTC member institu-
tions, which currently include 18 veteri-
nary academic centers, currently in the
United States.
Comparative oncology trials can answer
many questions within a single study. The
serial collection of tumor and normal
tissue biopsies and fluids from the same
animal before, during, and after exposure
to an investigational agent is feasible. This
sequential sampling allows the study of
tissue (tumor and/or surrounding normal
tissues) endpoints that may be linked to
surrogate imaging or circulating biomark-
ers, as a function of drug exposure or
therapeutic response, in ways that are
often difficult or unacceptable in human
trials. To ensure the integration of such
biological endpoints in these studies the
COTC Pharmacodynamic (PD) Core was
developed (http://ccr.cancer.gov/resourc-
es/cop/scientists/pharmacodynamic.asp).
The COTC PD Core provides infrastruc-
ture to support the development, valida-
tion, and assessment of pharmacokinetic,
pharmacodynamic, and biological end-
points within COTC trials. Through the
COTC and its PD Core, the opportunity
now exists to rapidly accrue pet dogs with
cancer to clinical trials that are detailed
and biologically intensive (http://ccr.can-
cer.gov/resources/cop/COTC.asp). The
first completed consortium trial was re-
cently published [23] and a 12th trial is
currently under development. In the
interest of open access to this approach
and its data, the COTC plans to publish
its trials in the journal PLoS ONE.
The Opportunity of the
Comparative Approach
Dogs have historically been useful,
informative models in the development
and discovery of many novel cancer
therapeutic strategies. The efficacy of
liposomal muramyl tripeptide phosphati-
dylethanolamine (L-MTP-PE) in dogs with
osteosarcoma served as part of the ratio-
nale for its evaluation in Phase III studies
in children. Indeed, similar results with L-
MTP-PE have been observed in both dogs
and children [24,25]. Dogs have been used
to develop and evaluate surgical limb
sparing techniques [26] and were valuable
models in the investigation of the combi-
nation of hyperthermia with radiation
[27,28]. Dogs have also been included in
the development of novel targeted anti-
cancer agents [20,29].
The similarities between dog and hu-
man cancers are increasingly being real-
ized. The publicly available canine ge-
nome has propelled comparative genomics
studies. Such studies have shown signifi-
cant homology between dog and human
for recognized cancer-associated genes
including MET, IGF1R, mTOR, and KIT
[9]. Not surprisingly, cytogenetic abnor-
malities that define human cancers, i.e.,
BCR-Abl translocations in chronic myelog-
enous leukemia and RB1 deletions in
chronic lymphocytic leukemia have been
found in comparable canine cancers [30].
These and other examples have been
recently reviewed elsewhere [9].
Integrating the comparative approach
has the opportunity to improve the
development path of new cancer drugs
(Figure 1). Drugs that may be less likely to
succeed in early human clinical trials may
be identified and culled early. For exam-
ple, the addition of comparative oncology
studies in the preclinical setting will
eliminate drugs with an unfavorable ther-
apeutic index or inferior target modulation
attributes, thus identifying agents most
likely to succeed in human Phase I trials.
Comparative studies performed during or
after human Phase I studies may focus on
pharmacokinetic/pharmacodynamic end-
points, classify responding patient subsets,
and identify optimal drug combinations.
These data may eliminate inactive drugs
before Phase II human trials and optimize
the design of these trials. Furthermore, the
integration of studies using pet dogs with
cancer provides a unique opportunity to
assess efficacy in the adjuvant or minimal
residual disease setting and, in so doing,
may prioritize those agents most likely to
be effective as Phase III human cancer
agents. Collectively, the elimination of
inferior drugs early in development will
reduce drug attrition in later phases of
human clinical development and result in
fewer human participants entering trials
with potentially ineffective or unsafe drugs.
By reducing the number of drugs entering
each phase of drug development and
increasing the success rate in Phase III
trials, an integrated approach can sub-
stantially decrease the costs and risks of
drug development (Figure 1).
Challenges and Limitations
As with all novel approaches and
perspectives, integrating studies with pet
dogs with cancer into the development
pathway is associated with some hesitation
and perception of risk. One of the goals of
the COTC is to define and address
perceived risks and actual challenges and
to mitigate them when possible.
N Timelines for the completion of a
study in pet dogs are longer than those
in rodent models. The multicenter
consortium that makes up the COTC
was developed to address this issue. By
integrating these studies into the de-
velopment pathway, human and pet
dog studies can be performed to
strategically prevent delays in the
conduct or completion of human
clinical trials.
N Reporting of data in a timely matter
is an important aspect of a clinical
trial. The COTC has developed an
electronic reporting system to acquire
data in real time and provide oversight
and monitoring of study results.
N Oversight guidelines of these types
of trials in pet dogs are not yet fully
defined. In all cases, the care of pet
animals must be given great consider-
ation and include institutional Animal
Care and Use Committee (ACUC)
approval. Trials are conducted in a
manner that prioritizes the medical
care and health of animals and re-
quires written owner consent. Reason-
able procedures for a given study are
assessed on a case by case basis and
may be overseen by a Data Safety
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with the ACUC. A working guide to
the conduct and regulatory reporting
of comparative trials is currently in
development.
N Study cost and budget must be
considered in the assessment of this
approach. The relatively larger size of
dogs mandates a concomitantly larger
drug supply for these trials than do
traditional murine studies. However,
preclinical trials of novel human can-
cer drugs do not require good manu-
facturing practice for drug use. Tu-
mor-bearing dog studies are more
expensive than mouse studies but are
within range of other large animal
Figure 1. An idealized view of the opportunity provided by a comparative and integrated oncology drug development path. This is
a theoretical illustration of 100 preclinical agents that may be evaluated by either a conventional or an integrated and comparative drug
development path. Data for transition rates and costs of Phase I, II, and III trials are based on published cost estimates [3] and reported clinical phase
transition probabilities for investigational oncology compounds from the 20 largest firms (by pharmaceutical sales in 2005) from 1993 to 2002 [2,4].
Estimates used to derive a vision of the benefit of an integrated approach to drug development are based, in part, on estimates of transition and
approval rates for non-oncology therapeutic areas where informative preclinical models exist [5]. Relative to the conventional development path, the
integrated development path is characterized by improved success early in clinical development and a reduction in drug failures late in clinical
development. Conventional oncology drug development results in approximately 40% of eligible agents transitioning from preclinical to Phase I, 75%
from Phase I to II, 60% from Phase II to III, and 55% from Phase III to approval [2]. Therefore, for every 100 preclinical candidates, only ten new drugs
will reach the clinic. Of most significance are failures that occur late in the development path (i.e., after Phase II or Phase III evaluation). With an
integrated approach, more toxic and ineffective agents may be eliminated prior to Phase I (estimate 30 agents now entering Phase I trials versus 40 in
the conventional pipeline). Attrition in Phase I may be minimized (estimated 87.5% success rate) and an additional 30% of drugs may be removed
from development prior to Phase II based on comparative studies that demonstrate poor pharmacokinetics, pharmacodynamics, or activity (estimate
18 agents now entering Phase II trials versus 30 in the conventional pipeline). Deprioritization (from above) of these drugs will improve the Phase II
success rate (estimate 90%). Data from comparative studies will result in the removal of 20% of remaining drugs prior to Phase III based on lack of
efficacy in the adjuvant setting, thereby improving success in Phase III and leading to 90% of Phase III agents receiving FDA approval (compared to
55% in the conventional pipeline). In this model, 12 new drugs out of every 100 preclinical candidates will reach the clinic. Using estimates for Phase I,
II, and III trials of US$15.2 million, US$23.5 million, and US$86.3 million per trial respectively [3], the total clinical trial expenditures for developing 100
preclinical agents is US$2.87 billion using conventional methods. Using the hypothetical improvements described above that result from the
integrated approach the clinical costs for development will be US$2.03 billion [3]. Factoring in additional costs for comparative studies with this
approach of US$150,000 for studies conducted in the preclinical setting, US$250,000 for studies conducted before or during Phases I–II human trials
and US$1 million for studies conducted before Phases II–III studies, the total cost of development is estimated at US$2.07 billion. The result may be a
decrease in average clinical trial costs per approved drug from US$290 million to US$173 million [5].
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tigational New Drug application. The
costs for these studies depend on the
trial design, which varies based on the
specific questions asked and answered.
Entry criteria and endpoints vary, but
most studies are powered similarly to
corresponding human Phase I/II trials
based on the statistical considerations
for the questions to be answered. The
addition of serial tumor biopsies,
imaging, or other correlative endpoints
incrementally add to study costs, but
these additions add value to the drug
development pathway previously not
recognized. If an integrated approach
is successful at prioritizing drugs in
development and optimizing human
clinical trials, these study costs will be
minor compared to the substantial
reduction in costs seen in human
clinical trials (Figure 1).
N Comparable histology is not al-
ways available in the comparative
approach. In dogs, the most common
tumors are sarcomas and lymphoid
neoplasms, whereas some of the com-
mon cancers of humans, namely
breast, prostate, gastrointestinal, and
lung carcinomas, are less common in
dogs. Clinical studies of these cancers
in dogs may need more time for
completion or addition of broader,
potentially international clinical trial
centers to enhance patient accrual. In
the future, it is likely that cancer
therapeutics will not be defined by
their activity within a particular histol-
ogy, but instead by a specific cancer
biology or dysregulation of a pathway
or gene. As such, a focus on common
histology might be replaced by one on
genetic or molecular similarities.
N Common targets for a therapy may
not always be readily known or
available for human and dog tumors.
Humanized antibodies and proteins
may not interact identically in dogs
or may be inactivated by their immune
system. In some cases, the dose
intensity of a drug, as used in humans,
may cause unacceptable toxicities in
dogs. For example, dogs are particu-
larly sensitive to the cremophor vehicle
used for paclitaxel. This has largely
limited the evaluation of conventional
taxanes in dogs.
The Future of the COTC and the
Comparative Approach
The increasing availability of banked
canine tumors and associated ‘‘omic’’
annotations for these cancers will allow
for rapid identification of valid tumor
targets in canine cancers. To this end, a
second community initiative, the Canine
Comparative Oncology and Genomics
Consortium (CCOGC; http://www.
ccogc.net/) was recently developed to
facilitate strategic partnerships and collab-
orations across a diversity of these disci-
plines and to develop a tissue biospecimen
repository. This repository has initiated
sample collections and expects to provide
tissues to the community in late 2009.
Proceeding forward, the COTC plans
to increase awareness of the applications of
the comparative approach. Through this
effort a greater understanding about the
diseases and treatment agents that are best
suited to this approach will be developed;
a broader integration of this approach into
the drug development and approval pro-
cess is expected to emerge; and an
acceleration of the development of effec-
tive new anticancer agents, devices, and
imaging techniques will occur. We believe
that such efforts will advance the quality of
care for both human and veterinary
cancer patients.
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